NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Wright JT, Harris-Haywood S, Pressel S, et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome. ALLHAT. Arch Intern Med 2008;168:207–217 What is the […]
Category Archives: Cardiovascular disease
NPC Archive Item: Calcium supplements may increase the risk of MI
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ Online First doi:10.1136/bmj.39440.525752.BE (published 15 January 2008) What […]
NPC Archive Item: Varenicline▼ compared with nicotine replacement therapy for smoking cessation
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Stapleton JA, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008;103:146-54. […]
NPC Archive Item: Coxibs or traditional NSAIDs for patients on low dose aspirin?
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Strand V. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 2007;370:2138–51 A recent review article in the […]
NPC Archive Item: Varenicline▼ safety update
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The Medicines and Healthcare products Regulatory Agency has announced an update to the product information for varenicline (Champix® ▼) highlighting concerns over suicidal thoughts and behaviour. Following a European […]
NPC Archive Item: Cardiovascular safety of glitazones in older people
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Lipscombe L, Gomes T, Lévesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007;298:2634-43. A large population-based study from Canada increases concerns over the […]
NPC Archive Item: Ezetimibe▼ in hypercholesterolaemia: NICE guidance
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. What is this about? NICE has published a technology appraisal covering ezetimibe▼ in hypercholesterolaemia. What do NICE say? NICE guidance relates only primary (heterozygous-familial or non-familial) hypercholesterolaemia, and not […]
NPC Archive Item: Awareness, agreement, adoption and adherence to hypertension guideline recommendations
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Heneghan C, et al. Hypertension guideline recommendations in general practice: awareness, agreement, adoption, and adherence. BJGP 2007;57:948–52 What is the background to this? This study aimed to understand GPs’ […]
NPC Archive Item: Current volume of angiotensin receptor blockers (ARBs) prescribing is not justified by the evidence
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Matchar DB, McCrory DC, Orlando LA, et al. Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin II Receptor Antagonists (ARBs) for Treating Essential Hypertension. Comparative Effectiveness Review No. […]
NPC Archive Item: Fibrates not first choice drugs for most patients, say MHRA and CHM
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Fibrates should not be used as first line lipid-lowering drugs for primary or secondary prevention of cardiovascular disease. So say the MHRA and CHM in the most recent issue […]